Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
An amended beneficial-ownership statement for AbCellera Biologics Inc. (ABCL) lists Carl L.G. Hansen, identified as a director, and Thermopylae Holdings Ltd. Hansen reported 65,913,149 shares (19.7%) beneficially owned, including 56,134,097 shares held by his wholly owned company, 898,000 shares held directly, and 8,881,052 shares issuable upon options exercisable within 60 days after September 30, 2026. Thermopylae reported 56,134,097 shares (17.2%) directly owned. AbCellera had 326,332,641 common shares outstanding as of September 30, 2026.
Hansen beneficial ownership65,913,149 shares19.7% of the class; includes shares issuable upon options exercisable within 60 days after September 30, 2026
Hansen ownership percentage19.7%Based on the stated beneficial-ownership amount and the filing's share-count methodology
Thermopylae directly owned shares56,134,097 sharesReported as 17.2% of the class
Thermopylae ownership percentage17.2%Based on 326,332,641 common shares outstanding as of September 30, 2026
Shares issuable upon options8,881,052 sharesOptions exercisable within 60 days after September 30, 2026
Common shares outstanding326,332,641 sharesAs of September 30, 2026
Key Terms
beneficially owned, sole voting power, sole dispositive power, Rule 13d-3(d)(1)(i)
4 terms
beneficially ownedregulatory
"Amount beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting powerregulatory
"Sole voting power: 65,913,149"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerregulatory
"Sole dispositive power: 65,913,149"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Rule 13d-3(d)(1)(i)regulatory
"added to the Common Shares outstanding in accordance with Rule 13d-3(d)(1)(i)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ABCL shares does Carl L.G. Hansen beneficially own?
Carl L.G. Hansen reported beneficial ownership of 65,913,149 AbCellera common shares, or 19.7%. The amount includes 56,134,097 shares held by Thermopylae Holdings Ltd., which he wholly owns, 898,000 shares held directly, and 8,881,052 shares issuable upon options exercisable within 60 days after September 30, 2026.
How many ABCL shares does Thermopylae Holdings Ltd. own?
Thermopylae Holdings Ltd. reported directly owning 56,134,097 AbCellera common shares, or 17.2%. The reported percentage is based on AbCellera's 326,332,641 common shares outstanding as of September 30, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
AbCellera Biologics Inc.
(Name of Issuer)
Common Shares, no par value per share
(Title of Class of Securities)
00288U106
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00288U106
1
Names of Reporting Persons
Carl L.G. Hansen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CANADA (FEDERAL LEVEL)
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
65,913,149.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
65,913,149.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
65,913,149.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
19.7 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
00288U106
1
Names of Reporting Persons
Thermopylae Holdings Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
BRITISH COLUMBIA, CANADA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
56,134,097.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
56,134,097.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
56,134,097.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
17.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
AbCellera Biologics Inc.
(b)
Address of issuer's principal executive offices:
150 W 4th Avenue, Vancouver, British Columbia, Canada V5Y 1G6
Item 2.
(a)
Name of person filing:
Carl L.G. Hansen
Thermopylae Holdings Ltd.
(b)
Address or principal business office or, if none, residence:
c/o AbCellera Biologics Inc.
150 W 4th Avenue
Vancouver, British Columbia, Canada V5Y 1G6
(c)
Citizenship:
Carl L.G. Hansen is a citizen of Canada. Thermopylae Holdings Ltd. is a company incorporated under the Business Corporations Act of British Columbia, Canada.
(d)
Title of class of securities:
Common Shares, no par value per share
(e)
CUSIP No.:
00288U106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Carl L.G. Hansen: 65,913,149 Common Shares. Dr. Hansen may be deemed to have voting and dispositive power over (i) 56,134,097 Common Shares directly owned by Thermopylae Holdings Ltd., which is wholly owned by Dr. Hansen, (ii) 898,000 Common Shares directly held by Dr. Hansen, and (iii) 8,881,052 Common Shares issuable to Dr. Hansen upon exercise of share options exercisable within 60 days after September 30, 2026.
Thermopylae Holdings Ltd.: 56,134,097 Common Shares directly owned.
(b)
Percent of class:
Carl L.G. Hansen: 19.7%. The percentage is based on (i) 326,332,641 Common Shares outstanding as of September 30, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed by the Issuer with the Securities and Exchange Commission on November 9, 2026, and (ii) 8,881,052 Common Shares issuable to Dr. Hansen upon exercise of share options exercisable within 60 days after September 30, 2026, which have been added to the Common Shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.
Thermopylae Holdings Ltd.: 17.2%. The percentage is based on 326,332,641 Common Shares outstanding as of September 30, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed by the Issuer with the Securities and Exchange Commission on November 9, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Carl L.G. Hansen: 65,913,149
Thermopylae Holdings Ltd.: 56,134,097
(ii) Shared power to vote or to direct the vote:
Carl L.G. Hansen: 0
Thermopylae Holdings Ltd.: 0
(iii) Sole power to dispose or to direct the disposition of:
Carl L.G. Hansen: 65,913,149
Thermopylae Holdings Ltd.: 56,134,097
(iv) Shared power to dispose or to direct the disposition of:
Carl L.G. Hansen: 0
Thermopylae Holdings Ltd.: 0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.